Instances of MTC in clients treated with liraglutide, A different GLP-one receptor agonist, have already been described in the postmarketing time period; the information in these experiences are inadequate to establish or exclude a causal connection among MTC and GLP-one receptor agonist use in individuals. • Improved Glucose Metabolism: By im